Clinical Edge Journal Scan

T2D: Bexagliflozin add-on to metformin shows antidiabetic potency equivalent to glimepiride


Key clinical point: As an adjunct to metformin, bexagliflozin (20 mg) demonstrated antidiabetic potency equivalent to titrated glimepiride in patients with type 2 diabetes (T2D) inadequately controlled on metformin. Additional benefits were demonstrated in the form of weight loss, reduced systolic blood pressure (SBP), and fewer hypoglycemic events.

Major finding: At week 60, the least squares mean difference in glycated hemoglobin levels between bexagliflozin and glimepiride was 0.05% (95% CI 0.21% to 0.11%), showing noninferiority of bexagliflozin over glimepiride; however, bexagliflozin was superior to glimepiride for weight loss (P < .0001), decrease in SBP (P = .0008), and hypoglycemia incidence (P < .0001).

Study details: This 96-week randomized controlled trial included 426 patients with T2D (7.0% ≤ A1c ≤ 10.5%) inadequately controlled on metformin who were randomly assigned to receive bexagliflozin (n = 213) or titrated glimepiride (n = 213).

Disclosures: This study was funded by Theracos Sub, LLC. Some authors including the lead author were supported by a research grant to the Massachusetts General Hospital from Theracos Sub, LLC.

Source: Halvorsen YD et al. A 96-week, double-blind, randomized, controlled trial comparing bexagliflozin to glimepiride as an adjunct to metformin for the treatment of type 2 diabetes in adults. Diabetes Obes Metab. 2022 (Sep 30). Doi: 10.1111/dom.14875

Recommended Reading

Drug repurposing ‘fast track’ to new medicines for obesity, diabetes
Type 2 Diabetes ICYMI
Yoga and other mind-body work good for diabetes control
Type 2 Diabetes ICYMI
Tirzepatide vs. insulin glargine improves renal outcomes in T2D
Type 2 Diabetes ICYMI
Antidiabetic drugs influence fracture risk in T2D
Type 2 Diabetes ICYMI
T2D: Increased risk for ventricular arrhythmia or sudden cardiac death with sulfonylurea vs metformin
Type 2 Diabetes ICYMI